Previsión
| Comprar |
3 |
| Mantener |
11 |
| Vender |
2 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Galapagos records 91% drop in revenue and launches strategic realignment
Galapagos reported a 91.3% decline in revenue for Q1 2026 to €6.5 million, primarily due to the loss of income from the agreement with Gilead. Despite the revenue shock, the company posted a net profit of €14.5 million, driven by positive currency effects and financial results. Management announced a comprehensive transformation including a renaming to Lakefront Biotherapeutics, a focus on innovative therapies such as Gamgertamig, and consideration of a share buyback as part of a new Gilead agreement. For 2026, Galapagos expects high expenses (including a prepayment to Gilead and costs related to the acquisition of Ouro Medicines) and forecasts year-end cash of between €1.975 billion and €2.05 billion. » Más en de.investing.com
RBC cuts Galapagos NV price target to $28, keeps Sector Perform ahead of Q1
RBC Capital Markets reduced its price target for Galapagos NV from $33 to $28 while maintaining a Sector Perform rating, citing seasonal pressures including reimbursement resets, gross-to-net dynamics, fewer selling days and potential weather-related disruptions. The bank noted that rising M&A activity and clearer drug-pricing expectations could help offset near-term volatility. Separately, Galapagos and Gilead agreed a binding framework related to Gilead’s acquisition of Ouro Medicines that expands collaboration rights and includes funding and operational arrangements. » Más en finance.yahoo.com
Galapagos signs agreement with Gilead on Ouro Medicines assets
Galapagos reached a binding agreement with Gilead tied to Gilead’s acquisition of Ouro Medicines, obtaining licenses to key IP, gamgertamig (a BCMAxCD3 T cell engager) and additional preclinical programs, plus related facilities and staff. The deal makes Galapagos responsible for early-stage development while later-stage costs and global commercialization (outside certain territories) will be shared with Gilead; Galapagos can receive milestone payments and tiered royalties of 20–23% on net sales. The company can independently deploy at least $500M of cash, including up to $150M for potential share buybacks. Gamgertamig has FDA Fast Track and Orphan Drug designations for AIHA and ITP and may enter registrational studies as early as 2027. Galapagos also proposed appointing Gino Santini as non-executive independent director and future chair, subject to shareholder approval. » Más en finance.yahoo.com
Galapagos and Gilead collaborate on Gamgertamig, unlock $500M and target 2027 registrational trials
Galapagos struck a binding collaboration with Gilead on BCMA x CD3 T‑cell engager Gamgertamig, with the companies splitting an upfront payment and milestone payments (including references to ~$1.675 billion and up to $500 million) and Galapagos eligible for up to $100 million in development milestones. The deal amends the legacy OLCA and unlocks an additional $500 million of Galapagos cash (including up to $150 million potentially available for return of capital); Gilead will hold commercialization rights outside Greater China while Galapagos gets 20%–23% royalties. Gamgertamig is in phase 1b (over 60 autoimmune patients treated, >160 across all trials), has Fast Track and Orphan designations for hemolytic anemia and ITP, and could enter registrational studies as early as 2027. Galapagos will fund development through initiation of registrational studies, after which costs are shared, and management says the transaction preserves strategic flexibility and leaves the majority of cash available for other opportunities. » Más en finance.yahoo.com
Galapagos exits cell therapy, shifts to business development with ~€3bn cash
Galapagos is winding down its cell therapy program and refocusing on business development in inflammation & immunology and oncology, backed by a refreshed leadership team and board. The company ended 2025 with about €2.998 billion in cash after recognizing €1.069 billion of deferred income tied to Gilead and taking ~€399.8 million of wind‑down and restructuring charges. TYK2 inhibitor GLPG3667 showed positive Phase 2 topline results in dermatomyositis and SLE, but Galapagos says it lacks full Phase 3 infrastructure and is seeking partners to advance the program. Management expects the cell therapy wind‑down to be largely complete by Q3 2026, anticipates one‑time restructuring cash costs of €125–175 million in 2026, and aims to be cash‑flow neutral to positive by year‑end 2026. » Más en finance.yahoo.com
Datos financieros
En el último trimestre, Galapagos tuvo unos ingresos de 7,42 M € y un beneficio neto de -2,61 M €
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 7,42 M | 89,58 % |
| Beneficio bruto | 3,82 M | 93,67 % |
| Beneficio neto | -2,61 M | 98,71 % |
| EBITDA | -39,84 M | 78,98 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 2108,1 M € |
Número de acciones | 65,9 M |
Máximo/mínimo de 52 semanas | 31,99 € - 23,88 € |
| Dividendos | No |
Beta | 0,11 |
Ratio P/E | 4,18 |
Ratio PEG | -0,11 |
Ratio P/B | 0,63 |
Ratio P/S | 1,94 |
Perfil de la empresa
Galapagos NV, una empresa biofarmacéutica integrada, se dedica al descubrimiento, desarrollo y comercialización de diversos medicamentos para cubrir necesidades médicas elevadas no atendidas. Entre los productos de su cartera en desarrollo se encuentra filgotinib, un inhibidor de JAK1 que se encuentra en distintas fases de ensayos clínicos para el tratamiento de la artritis reumatoide, la enfermedad de Crohn, la colitis ulcerosa, la EC del intestino delgado, la EC fistulizante, la espondilitis anquilosante, la artritis psoriásica y la uveítis. Los productos de la cartera de la empresa también incluyen GLPG1972, que ha completado un ensayo de fase 2b para el tratamiento de la osteoartritis; las moléculas Toledo, entre ellas GLPG3970, GLPG4399 y GLPG4876, para la inflamación; y GLPG4716 y ziritaxestat para el tratamiento de la fibrosis pulmonar idiopática. Además, otros productos de su cartera incluyen GLPG2737, un regulador de la conductancia transmembrana de la fibrosis quística que se encuentra en ensayos clínicos de fase 2 para tratar a pacientes con enfermedad renal poliquística autosómica dominante; y GLPG0555, un inhibidor de JAK1, que se encuentra en fase 1b para el tratamiento de pacientes con osteoartritis. La empresa tiene acuerdos de colaboración con Gilead Sciences, Inc.; AbbVie S.à r.l.; y Novartis Pharma AG. Galapagos NV se constituyó en 1999 y tiene su sede en Mechelen, Bélgica.
| Nombre | Galapagos |
| CEO | Henry Gosebruch |
| Sede | Mechelen,
bu Bélgica |
| Sitio web | |
| Sector | Salud |
| Industria | Biotecnología |
| Salida a bolsa | 06/05/2005 |
| Empleados | 452 |
Deep Dive
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
Euronext | GLPG.AS |
Pnk | GLPGF |
Amsterdam | GLPG.AS |
Frankfurt | GXE.F |
Düsseldorf | GXE.DU |
London | 0JXZ.L |
München | GXE.MU |
Wien | GLPG.VI |